These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32110122)

  • 21. Low utilization of statins in patients with dermatomyositis/polymyositis and hyperlipidemia: a multicenter USA-based study (2013-2023).
    Fares J; Summer R; Loizidis G
    Clin Rheumatol; 2024 Jan; 43(1):325-338. PubMed ID: 37930595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acthar Gel (repository corticotropin injection) for persistently active SLE: study design and baseline characteristics from a multicentre, randomised, double-blind, placebo-controlled trial.
    Askanase AD; Zhao E; Zhu J; Connolly-Strong E; Furie RA
    Lupus Sci Med; 2020; 7(1):e000383. PubMed ID: 32399253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient Characteristics and Indicators of Treatment Initiation with Repository Corticotropin Injection in Patients with Rheumatoid Arthritis: A Claims Database Analysis.
    Hayes K; Panaccio MP; Goel N; Fahim M
    Rheumatol Ther; 2021 Mar; 8(1):327-346. PubMed ID: 33400194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repository corticotropin injection as adjunctive therapy in patients with rheumatoid arthritis who have failed previous therapies with at least three different modes of action.
    Gillis T; Crane M; Hinkle C; Wei N
    Open Access Rheumatol; 2017; 9():131-138. PubMed ID: 28790870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The host defense peptide LL-37 a possible inducer of the type I interferon system in patients with polymyositis and dermatomyositis.
    Lu X; Tang Q; Lindh M; Dastmalchi M; Alexanderson H; Popovic Silwerfeldt K; Agerberth B; Lundberg IE; Wick C
    J Autoimmun; 2017 Mar; 78():46-56. PubMed ID: 28012697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Repository Corticotropin Injection on Medication Use in Patients With Rheumatologic Conditions: A Claims Data Study.
    Myung G; Nelson WW; McMahon MA
    J Pharm Technol; 2017 Aug; 33(4):151-155. PubMed ID: 34861677
    [No Abstract]   [Full Text] [Related]  

  • 27. Association of systemic and thyroid autoimmune diseases.
    Biró E; Szekanecz Z; Czirják L; Dankó K; Kiss E; Szabó NA; Szucs G; Zeher M; Bodolay E; Szegedi G; Bakó G
    Clin Rheumatol; 2006 Mar; 25(2):240-5. PubMed ID: 16247581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus.
    Askanase AD; Wright D; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Dec; 8(4):1871-1886. PubMed ID: 34478124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases.
    Chikazawa H; Nishiya K; Matsumori A; Hashimoto K
    J Clin Immunol; 2000 Jul; 20(4):279-86. PubMed ID: 10939715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and laboratory features of overlap syndromes of idiopathic inflammatory myopathies associated with systemic lupus erythematosus, systemic sclerosis, or rheumatoid arthritis.
    Aguila LA; Lopes MR; Pretti FZ; Sampaio-Barros PD; Carlos de Souza FH; Borba EF; Shinjo SK
    Clin Rheumatol; 2014 Aug; 33(8):1093-8. PubMed ID: 24989017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: a nationally representative cohort study.
    Hsu CY; Ko CH; Wang JL; Hsu TC; Lin CY
    Arthritis Res Ther; 2019 Oct; 21(1):211. PubMed ID: 31604447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Large macrophage colony-forming cells identical to high proliferative potential colony-forming cells in peripheral blood of patients with collagen vascular diseases: high occurrence among patients with systemic sclerosis and dermatomyositis.
    Horie S; Minota S; Kano S
    J Rheumatol; 2000 Oct; 27(10):2378-81. PubMed ID: 11036833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States.
    Nelson WW; Lima AF; Kranyak J; Opong-Owusu B; Ciepielewska G; Gallagher JR; Heap K; Carroll S
    J Ocul Pharmacol Ther; 2019 Apr; 35(3):182-188. PubMed ID: 30676837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of plexin D1 on circulating extracellular vesicles as a potential biomarker of polymyositis and dermatomyositis.
    Uto K; Ueda K; Okano T; Akashi K; Takahashi S; Nakamachi Y; Imanishi T; Awano H; Morinobu A; Kawano S; Saegusa J
    Rheumatology (Oxford); 2022 Apr; 61(4):1669-1679. PubMed ID: 34297034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repository corticotropin injection in patients with persistently active SLE requiring corticosteroids: post hoc analysis of results from a two-part, 52-week pilot study.
    Furie RA; Mitrane M; Zhao E; Becker PM
    Lupus Sci Med; 2017; 4(1):e000240. PubMed ID: 29344387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology and mortality of connective tissue disease-associated pulmonary arterial hypertension: A national cohort study in taiwan.
    Lin CY; Ko CH; Hsu CY; Chen HA
    Semin Arthritis Rheum; 2020 Oct; 50(5):957-962. PubMed ID: 32906031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis.
    Fleischmann R; Hayes K; Ahn SW; Wan GJ; Panaccio M; Karlsson D; Furst DE
    Rheumatol Ther; 2022 Apr; 9(2):649-661. PubMed ID: 35184268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records.
    Chopra I; Qin Y; Kranyak J; Gallagher JR; Heap K; Carroll S; Wan GJ
    Ther Adv Respir Dis; 2019; 13():1753466619888127. PubMed ID: 31722624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repository corticotropin injection attenuates collagen-induced arthritic joint structural damage and has enhanced effects in combination with etanercept.
    Decker DA; Higgins P; Hayes K; Bollinger C; Becker P; Wright D
    BMC Musculoskelet Disord; 2020 Aug; 21(1):586. PubMed ID: 32867752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial.
    Fleischmann R; Furst DE; Connolly-Strong E; Liu J; Zhu J; Brasington R
    Rheumatol Ther; 2020 Jun; 7(2):327-344. PubMed ID: 32185745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.